Healthy Skepticism Library item: 6269

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Grabowski HG, Wang YR.
The quantity and quality of worldwide new drug introductions, 1982-2003.
Health Aff (Millwood) 2006 Mar-Apr 01; 25:(2):452-60
http://content.healthaffairs.org/cgi/content/full/25/2/452

Abstract:

We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.

Keywords:
Biotechnology Drug Industry* Drugs, Investigational/standards Drugs, Investigational/supply & distribution* Europe Humans Investigational New Drug Application/statistics & numerical data* Orphan Drug Production Research Support, Non-U.S. Gov't United States World Health